The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

817074816150814013c3112c58-eb52-4515-b778-ed0eefe8cdcdcf9e0033-2d30-4556-952b-62134d6d66aac2848a4a-9c02-4194-878f-953bb35636dfARGS_News_2015_3_20_General_Releases.pdfARGS_News_2015_3_16_General_Releases.pdfARGS_News_2015_3_4_General_Releases.pdf1999017201156371232015-3-20T8:30:0-4:02015-3-16T16:30:0-4:02015-3-4T16:30:0-4:0902658901854900038General ReleasesGeneral ReleasesGeneral ReleasesDr. Mark DeBenedette Will Review Outcomes From a Phase IIb Clinical Trial of Investigational Immunotherapy for the Treatment of HIVArgos Therapeutics Director of Immunology to Present at HIV Vaccines MeetingArgos Therapeutics to Hold Fourth Quarter and Year-End 2014 Financial Results Conference Call on Monday, March 30, 2015Argos Therapeutics to Present at Three Upcoming Investor Conferences in March878787201520152015No Error0

Argos Therapeutics Director of Immunology to Present at HIV Vaccines Meeting
Read more

Argos Therapeutics to Hold Fourth Quarter and Year-End 2014 Financial Results Conference Call on Monday, March 30, 2015
Read more

Argos Therapeutics to Present at Three Upcoming Investor Conferences in March
Read more

> More News & Events Here.

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC